{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:05:33Z","timestamp":1791021933169,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Approved KRAS inhibitors have shown limited therapeutic benefit over standard chemotherapy in PDAC and often encounter acquired resistance due to additional genetic alterations. RAS and RB1 functionally antagonize each other, which explains why RB1 is rarely mutated in KRAS-driven tumors. In PDAC cells, CDK4\/6 inhibition induced cellular senescence accompanied by partial apoptosis. However, additional treatment with a senolytic agent or an ERK inhibitor promoted more efficient tumor cell elimination. While CDK4\/6 inhibition downregulated KRAS activity, it concurrently upregulated EGFR signaling in a SASP and JNK-dependent manner. Deprivation of EGFR signaling after CDK4\/6 inhibition triggered apoptosis in senescent cells in a manner similar to the treatment with a senolytic agent. In contrast, specific inhibition of KRAS induced modest enhancement of EGFR activity and SASP in a JNK-independent manner. Collectively, our study proposes that the CDK4\/6 inhibitor may achieve greater therapeutic efficacy when combined with the EGFR inhibitor than KRAS inhibitor monotherapy.<\/jats:p>","DOI":"10.1038\/s41418-025-01634-0","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:00:46Z","timestamp":1766066446000},"page":"1218-1233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Deprivation of EGFR signal causes senolysis in PDAC with CDK4\/6 inhibition"],"prefix":"10.1038","volume":"33","author":[{"given":"Yuanyuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1448-9527","authenticated-orcid":false,"given":"Susumu","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keqi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahadi","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2161-2087","authenticated-orcid":false,"given":"Tomohisa","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Sankoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjian","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3733-260X","authenticated-orcid":false,"given":"Noriko","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7216-3958","authenticated-orcid":false,"given":"Jindan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takiko","family":"Daikoku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6812-9607","authenticated-orcid":false,"given":"Yoshikazu","family":"Johmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3390-9563","authenticated-orcid":false,"given":"Chiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"1634_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","volume":"21","author":"L Morrison","year":"2024","unstructured":"Morrison L, Loibl S, Turner NC. The CDK4\/6 inhibitor revolution - a game-changing era for breast cancer treatment. Nat Rev Clin Oncol. 2024;21:89\u2013105.","journal-title":"Nat Rev Clin Oncol"},{"key":"1634_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425\u201339.","journal-title":"Lancet Oncol"},{"key":"1634_CR3","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc1495","volume":"375","author":"A Fassl","year":"2022","unstructured":"Fassl A, Geng Y, Sicinski P. CDK4 and CDK6 kinases: From basic science to cancer therapy. Science. 2022;375:eabc1495.","journal-title":"Science"},{"key":"1634_CR4","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","volume":"22","author":"S Goel","year":"2022","unstructured":"Goel S, Bergholz JS, Zhao JJ. Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer. 2022;22:356\u201372.","journal-title":"Nat Rev Cancer"},{"key":"1634_CR5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41586-023-06274-3","volume":"619","author":"JA Cornwell","year":"2023","unstructured":"Cornwell JA, Crncec A, Afifi MM, Tang K, Amin R, Cappell SD. Loss of CDK4\/6 activity in S\/G2 phase leads to cell cycle reversal. Nature. 2023;619:363\u201370.","journal-title":"Nature"},{"key":"1634_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-022-01510-6","volume":"24","author":"AC Watt","year":"2022","unstructured":"Watt AC, Goel S. Cellular mechanisms underlying response and resistance to CDK4\/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Breast Cancer Res. 2022;24:17.","journal-title":"Breast Cancer Res"},{"key":"1634_CR7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, et al. CDK4\/6 inhibition triggers anti-tumour immunity. Nature. 2017;548:471\u20135.","journal-title":"Nature"},{"key":"1634_CR8","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","volume":"37","author":"M \u00c1lvarez-Fern\u00e1ndez","year":"2020","unstructured":"\u00c1lvarez-Fern\u00e1ndez M, Malumbres M. Mechanisms of sensitivity and resistance to CDK4\/6 inhibition. Cancer Cell. 2020;37:514\u201329.","journal-title":"Cancer Cell"},{"key":"1634_CR9","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1002\/hep.31872","volume":"74","author":"J Sheng","year":"2021","unstructured":"Sheng J, Kohno S, Okada N, Okahashi N, Teranishi K, Matsuda F, et al. Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4\/6 Inhibitor Combination Therapy. Hepatology. 2021;74:1971\u201393.","journal-title":"Hepatology"},{"key":"1634_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/386177a0","volume":"386","author":"DS Peeper","year":"1997","unstructured":"Peeper DS, Upton TM, Ladha MH, Neuman E, Zalvide J, Bernards R, et al. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature. 1997;386:177\u201381.","journal-title":"Nature"},{"key":"1634_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0960-9822(97)70094-0","volume":"7","author":"S Mittnacht","year":"1997","unstructured":"Mittnacht S, Paterson H, Olson MF, Marshall CJ. Ras signalling is required for inactivation of the tumour suppressor pRb cell-cycle control protein. Curr Biol. 1997;7:219\u201321.","journal-title":"Curr Biol"},{"key":"1634_CR12","doi-asserted-by":"publisher","first-page":"7724","DOI":"10.1128\/MCB.19.11.7724","volume":"19","author":"KY Lee","year":"1999","unstructured":"Lee KY, Ladha MH, McMahon C, Ewen ME. The retinoblastoma protein is linked to the activation of Ras. Mol Cell Biol. 1999;19:7724\u201332.","journal-title":"Mol Cell Biol"},{"key":"1634_CR13","doi-asserted-by":"publisher","first-page":"9345","DOI":"10.1158\/0008-5472.CAN-06-1250","volume":"66","author":"C Takahashi","year":"2006","unstructured":"Takahashi C, Ewen ME. Genetic interaction between Rb and N-ras: differentiation control and metastasis. Cancer Res. 2006;66:9345\u20138.","journal-title":"Cancer Res"},{"key":"1634_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ccr.2009.03.007","volume":"15","author":"DS Peeper","year":"2009","unstructured":"Peeper DS. Ras and pRb: the relationship gets yet more intimate. Cancer Cell. 2009;15:243\u20135.","journal-title":"Cancer Cell"},{"key":"1634_CR15","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1097-2765(01)00194-0","volume":"7","author":"CJ Ceol","year":"2001","unstructured":"Ceol CJ, Horvitz HR. dpl-1 DP and efl-1 E2F act with lin-35 Rb to antagonize Ras signaling in C. elegans vulval development. Mol Cell. 2001;7:461\u201373.","journal-title":"Mol Cell"},{"key":"1634_CR16","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1128\/MCB.23.15.5256-5268.2003","volume":"23","author":"C Takahashi","year":"2003","unstructured":"Takahashi C, Bronson RT, Socolovsky M, Contreras B, Lee KY, Jacks T, et al. Rb and N-ras function together to control differentiation in the mouse. Mol Cell Biol. 2003;23:5256\u201368.","journal-title":"Mol Cell Biol"},{"key":"1634_CR17","doi-asserted-by":"publisher","first-page":"10406","DOI":"10.1128\/MCB.24.23.10406-10415.2004","volume":"24","author":"C Takahashi","year":"2004","unstructured":"Takahashi C, Contreras B, Bronson RT, Loda M, Ewen ME, et al. Genetic interaction between Rb and K-ras in the control of differentiation and tumor suppression. Mol Cell Biol. 2004;24:10406\u201315.","journal-title":"Mol Cell Biol"},{"key":"1634_CR18","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/ng1703","volume":"38","author":"C Takahashi","year":"2006","unstructured":"Takahashi C, Contreras B, Iwanaga T, Takegami Y, Bakker A, Bronson RT, et al. Nras loss induces metastatic conversion of Rb1-deficient neuroendocrine thyroid tumor. Nat Genet. 2006;38:118\u201323.","journal-title":"Nat Genet"},{"key":"1634_CR19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ccr.2009.03.001","volume":"15","author":"A Shamma","year":"2009","unstructured":"Shamma A, Takegami Y, Miki T, Kitajima S, Noda M, Obara T, et al. Rb Regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation. Cancer Cell. 2009;15:255\u201369.","journal-title":"Cancer Cell"},{"key":"1634_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"Cancer Genome Atlas Research Network","year":"2017","unstructured":"Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017;32:185\u2013203.","journal-title":"Cancer Cell"},{"key":"1634_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, et al. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med. 2023;388:33\u201343.","journal-title":"N Engl J Med"},{"key":"1634_CR22","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","volume":"19","author":"SR Punekar","year":"2022","unstructured":"Punekar SR, Velcheti V, Neel BG, Wong KK. The current state of the art and future trends in RAS-targeted cancer therapies. Nat Rev Clin Oncol. 2022;19:637\u201355.","journal-title":"Nat Rev Clin Oncol"},{"key":"1634_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-024-01631-9","volume":"17","author":"X Yang","year":"2024","unstructured":"Yang X, Wu H. RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms. J Hematol Oncol. 2024;17:108.","journal-title":"J Hematol Oncol"},{"key":"1634_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","volume":"619","author":"D Kim","year":"2023","unstructured":"Kim D, Herdeis L, Rudolph D, Zhao Y, B\u00f6ttcher J, Vides A, et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature. 2023;619:160\u20136.","journal-title":"Nature"},{"key":"1634_CR25","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRASG12C Inhibition with sotorasib in Advanced Solid Tumors. N Engl J Med. 2020;383:1207\u201317.","journal-title":"N Engl J Med"},{"key":"1634_CR26","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, et al. Acquired Resistance to KRASG12C Inhibition in Cancer. N Engl J Med. 2021;384:2382\u201393.","journal-title":"N Engl J Med"},{"key":"1634_CR27","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","volume":"11","author":"N Tanaka","year":"2021","unstructured":"Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, et al. Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. Cancer Discov. 2021;11:1913\u201322.","journal-title":"Cancer Discov"},{"key":"1634_CR28","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.cell.2020.03.008","volume":"181","author":"M Ruscetti","year":"2020","unstructured":"Ruscetti M, Morris JP 4th, Mezzadra R, Russell J, Leibold J, Romesser PB, et al. Senescence-induced vascular remodeling creates therapeutic vulnerabilities in pancreas cancer. Cell. 2020;181:424\u201341.","journal-title":"Cell"},{"key":"1634_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1158\/0008-5472.CAN-22-0391","volume":"83","author":"CM Goodwin","year":"2023","unstructured":"Goodwin CM, Waters AM, Klomp JE, Javaid S, Bryant KL, Stalnecker CA, et al. Combination therapies with CDK4\/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. Cancer Res. 2023;83:141\u201357.","journal-title":"Cancer Res"},{"key":"1634_CR30","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","volume":"14","author":"J Dilly","year":"2024","unstructured":"Dilly J, Hoffman MT, Abbassi L, Li Z, Paradiso F, Parent BD, et al. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. Cancer Discov. 2024;14:2135\u201361.","journal-title":"Cancer Discov"},{"key":"1634_CR31","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"1634_CR32","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/S1470-2045(25)00363-8","volume":"26","author":"QP Janssen","year":"2025","unstructured":"Janssen QP, van Dam JL, van Bekkum ML, Bonsing BA, Bos H, Bosscha KP, et al. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial. Lancet Oncol. 2025;26:1346\u201356.","journal-title":"Lancet Oncol"},{"key":"1634_CR33","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/acel.12445","volume":"15","author":"Y Zhu","year":"2016","unstructured":"Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, Dai HM, Ling YY, Stout MB, et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell. 2016;15:428\u201335.","journal-title":"Aging Cell"},{"key":"1634_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106628","volume":"187","author":"A Estepa-Fern\u00e1ndez","year":"2023","unstructured":"Estepa-Fern\u00e1ndez A, Garc\u00eda-Fern\u00e1ndez A, L\u00e9rida-Viso A, Blandez JF, Galiana I, Sancenon-Galarza F, et al. Combination of palbociclib with navitoclax based-therapies enhances in vivo antitumoral activity in triple-negative breast cancer. Pharm Res. 2023;187:106628.","journal-title":"Pharm Res"},{"key":"1634_CR35","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92352","volume":"3","author":"SJ Moschos","year":"2018","unstructured":"Moschos SJ, Sullivan RJ, Hwu WJ, Ramanathan RK, Adjei AA, Fong PC, et al. Development of MK-8353, an orally administered ERK1\/2 inhibitor, in patients with advanced solid tumors. JCI Insight. 2018;3:e92352.","journal-title":"JCI Insight"},{"key":"1634_CR36","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1021\/acsmedchemlett.8b00220","volume":"9","author":"SB Boga","year":"2018","unstructured":"Boga SB, Deng Y, Zhu L, Nan Y, Cooper AB, Shipps GW Jr, et al. MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology. ACS Med Chem Lett. 2018;9:761\u20137.","journal-title":"ACS Med Chem Lett"},{"key":"1634_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq4274","volume":"10","author":"X Song","year":"2024","unstructured":"Song X, Zhou Z, Elmezayen A, Wu R, Yu C, Gao B, et al. SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition. Sci Adv. 2024;10:eadq4274.","journal-title":"Sci Adv"},{"key":"1634_CR38","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.molcel.2012.08.011","volume":"48","author":"AK Rouquette-Jazdanian","year":"2012","unstructured":"Rouquette-Jazdanian AK, Sommers CL, Kortum RL, Morrison DK, Samelson LE. LAT-independent Erk activation via Bam32-PLC-\u03b31-Pak1 complexes: GTPase-independent Pak1 activation. Mol Cell. 2012;48:298\u2013312.","journal-title":"Mol Cell"},{"key":"1634_CR39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0014-4827(02)00105-2","volume":"284","author":"RC Harris","year":"2003","unstructured":"Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res. 2003;284:2\u201313.","journal-title":"Exp Cell Res"},{"key":"1634_CR40","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1074\/jbc.275.1.557","volume":"275","author":"J Dong","year":"2000","unstructured":"Dong J, Wiley HS. Trafficking and proteolytic release of epidermal growth factor receptor ligands are modulated by their membrane-anchoring domains. J Biol Chem. 2000;275:557\u201364.","journal-title":"J Biol Chem"},{"key":"1634_CR41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.febslet.2004.06.056","volume":"571","author":"HM Shin","year":"2004","unstructured":"Shin HM, Kim MH, Kim BH, Jung SH, Kim YS, Park HJ, et al. Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-kappaB without affecting IkappaB degradation. FEBS Lett. 2004;571:50\u201354.","journal-title":"FEBS Lett"},{"key":"1634_CR42","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41568-019-0156-2","volume":"19","author":"DV Faget","year":"2019","unstructured":"Faget DV, Ren Q, Stewart SA. Unmasking senescence: context-dependent effects of SASP in cancer. Nat Rev Cancer. 2019;19:439\u201353.","journal-title":"Nat Rev Cancer"},{"key":"1634_CR43","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.3390\/ijms20102515","volume":"20","author":"R Thomas","year":"2019","unstructured":"Thomas R, Srivastava S, Katreddy RR, Sobieski J, Weihua Z. Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors. Int J Mol Sci. 2019;20:2515.","journal-title":"Int J Mol Sci"},{"key":"1634_CR44","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/sj.bjc.6602793","volume":"93","author":"MW Pedersen","year":"2005","unstructured":"Pedersen MW, Pedersen N, Ottesen LH, Poulsen HS. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer. 2005;93:915\u201323.","journal-title":"Br J Cancer"},{"key":"1634_CR45","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ccell.2020.01.007","volume":"37","author":"B Salvador-Barbero","year":"2020","unstructured":"Salvador-Barbero B, \u00c1lvarez-Fern\u00e1ndez M, Zapatero-Solana E, El Bakkali A, Men\u00e9ndez MDC, L\u00f3pez-Casas PP, et al. CDK4\/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. Cancer Cell. 2020;37:340\u201353.","journal-title":"Cancer Cell"},{"key":"1634_CR46","doi-asserted-by":"publisher","first-page":"9056","DOI":"10.1021\/acs.jmedchem.1c00159","volume":"64","author":"KD Freeman-Cook","year":"2021","unstructured":"Freeman-Cook KD, Hoffman RL, Behenna DC, Boras B, Carelli J, Diehl W, et al. Discovery of PF-06873600, a CDK2\/4\/6 Inhibitor for the Treatment of Cancer. J Med Chem. 2021;64:9056\u201377.","journal-title":"J Med Chem"},{"key":"1634_CR47","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/onc.2009.355","volume":"29","author":"JJ Lee","year":"2010","unstructured":"Lee JJ, Lee JH, Ko YG, Hong SI, Lee JS. Prevention of premature senescence requires JNK regulation of Bcl-2 and reactive oxygen species. Oncogene. 2010;29:561\u201375.","journal-title":"Oncogene"},{"key":"1634_CR48","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3390\/metabo11060379","volume":"11","author":"B Molloy","year":"2021","unstructured":"Molloy B, Mullin L, King A, Gethings LA, Plumb RS, Wilson ID. The Pharmacometabodynamics of Gefitinib after Intravenous Administration to Mice: A Preliminary UPLC-IM-MS Study. Metabolites. 2021;11:379.","journal-title":"Metabolites"},{"key":"1634_CR49","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1080\/00498254.2020.1859643","volume":"51","author":"BJ Molloy","year":"2021","unstructured":"Molloy BJ, King A, Mullin LG, Gethings LA, Riley R, Plumb RS, et al. Rapid determination of the pharmacokinetics and metabolic fate of gefitinib in the mouse using a combination of UPLC\/MS\/MS, UPLC\/QToF\/MS, and ion mobility (IM)-enabled UPLC\/QToF\/MS. Xenobiotica. 2021;51:434\u201346.","journal-title":"Xenobiotica"},{"key":"1634_CR50","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","volume":"7","author":"SR Hingorani","year":"2005","unstructured":"Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7:469\u201383.","journal-title":"Cancer Cell"},{"key":"1634_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04449-5","volume":"9","author":"H Shibata","year":"2018","unstructured":"Shibata H, Komura S, Yamada Y, Sankoda N, Tanaka A, Ukai T, et al. In vivo reprogramming drives Kras-induced cancer development. Nat Commun. 2018;9:2081.","journal-title":"Nat Commun"},{"key":"1634_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06040-3","volume":"14","author":"K Yang","year":"2023","unstructured":"Yang K, Li X, Xie K. Senescence program and its reprogramming in pancreatic premalignancy. Cell Death Dis. 2023;14:528.","journal-title":"Cell Death Dis"},{"key":"1634_CR53","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/BF01002772","volume":"11","author":"LC Junqueira","year":"1979","unstructured":"Junqueira LC, Bignolas G, Brentani RR. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J. 1979;11:447\u201355.","journal-title":"Histochem J"},{"key":"1634_CR54","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1158\/1078-0432.CCR-11-3114","volume":"18","author":"C Feig","year":"2012","unstructured":"Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Re. 2012;18:4266\u201376.","journal-title":"Clin Cancer Re"},{"key":"1634_CR55","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/(SICI)1096-9896(199803)184:3<234::AID-PATH28>3.0.CO;2-D","volume":"184","author":"L Bouwens","year":"1998","unstructured":"Bouwens L. Cytokeratins and cell differentiation in the pancreas. J Pathol. 1998;184:234\u20139.","journal-title":"J Pathol"},{"key":"1634_CR56","first-page":"559","volume":"140","author":"MH Sch\u00fcssler","year":"1992","unstructured":"Sch\u00fcssler MH, Skoudy A, Ramaekers F, Real FX. Intermediate filaments as differentiation markers of normal pancreas and pancreas cancer. Am J Pathol. 1992;140:559\u201368.","journal-title":"Am J Pathol"},{"key":"1634_CR57","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/sj.bjc.6600879","volume":"88","author":"T Ueno","year":"2003","unstructured":"Ueno T, Linder S, Elmberger G. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer. 2003;88:1229\u201333.","journal-title":"Br J Cancer"},{"key":"1634_CR58","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.cmet.2020.09.006","volume":"32","author":"S Omori","year":"2020","unstructured":"Omori S, Wang TW, Johmura Y, Kanai T, Nakano Y, Kido T, et al. Generation of a p16 Reporter Mouse and Its Use to Characterize and Target p16high Cells In Vivo. Cell Metab. 2020;32:814\u201328.","journal-title":"Cell Metab"},{"key":"1634_CR59","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","volume":"13","author":"MV Negrao","year":"2023","unstructured":"Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, et al. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023;13:1556\u201371.","journal-title":"Cancer Discov"},{"key":"1634_CR60","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375:1738\u201348.","journal-title":"N Engl J Med"},{"key":"1634_CR61","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:77\u201390.","journal-title":"Lancet Oncol"},{"key":"1634_CR62","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.lungcan.2019.09.002","volume":"137","author":"B Besse","year":"2019","unstructured":"Besse B, Barlesi F, Demedts I, Fuentes Pradera J, Robinet G, Gazzah A, et al. A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer. Lung Cancer. 2019;137:136\u201343.","journal-title":"Lung Cancer"},{"key":"1634_CR63","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.lungcan.2022.02.010","volume":"166","author":"A Santoro","year":"2022","unstructured":"Santoro A, Su WC, Navarro A, Simonelli M, Ch Yang J, Ardizzoni A, et al. Phase Ib\/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer. Lung Cancer. 2022;166:170\u20137.","journal-title":"Lung Cancer"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01634-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01634-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01634-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:02:26Z","timestamp":1780934546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01634-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1634"],"URL":"https:\/\/doi.org\/10.1038\/s41418-025-01634-0","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Approval has been obtained from the Institutional Biosafety Committee of Kanazawa University (KU6-2807) and the Experimental Animals and Use Committee of Kanazawa University (AP25-012). No experiments using samples from patients have been performed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participant"}}]}}